Introduction {#sec1}
============

*Staphylococcus aureus* infection is the most common fatal bacterial infection in neonates worldwide ([@bib1]). The infection can result in endocarditis, pneumonia, osteomyelitis, and septic shock ([@bib2]). In recent years, antibiotic-resistant strains of *S. aureus* have emerged, limiting treatment options for life-threatening *S. aureus* infections in infants ([@bib2]). A clinical trial ([@bib3]) and subsequent meta-analysis ([@bib4]) showed that orally administered bovine lactoferrin (bLf) reduced the incidence of late-onset sepsis in very-low-birth-weight infants colonized with gram-positive bacteria, including *Staphylococcus* species ([@bib3]).

The role of lactoferrin in the immune response and infection has recently been reviewed ([@bib5], [@bib6]). These effects likely occur in the intestinal lumen as well as through direct effects on immune cells because bLf is resistant to proteolytic digestion ([@bib7], [@bib8]) and because both piglet and human intestinal epithelial cells express lactoferrin receptors ([@bib9]--[@bib11]). Although the mechanism of action whereby dietary bLf reduces *S. aureus* infection is unknown, several modes of action are plausible. First, lactoferrin is an iron-binding glycoprotein, which may exert antimicrobial effects by preventing microbes from accessing adequate iron. Lactoferrin is also released by neutrophils at the sites of injury or infection. The release of lactoferrin inhibits infiltration of inflammatory neutrophils while attracting monocytes, suggesting that lactoferrin plays an important role in regulating inflammation, thereby preventing sepsis without inhibiting the original immune response ([@bib12]). In addition to having effects on the early immune response, reports in the literature suggest that lactoferrin is important in generating a T-helper 1 (Th1) adaptive immune response in mice ([@bib13], [@bib14]) and piglets ([@bib15]). A Th1 adaptive response would favor a cellular-immune response to intracellular *S. aureus* that would increase bacterial clearance from tissues. Lactoferrin also promotes the growth of beneficial commensal bacteria of the *Bifidobacteria* spp., especially *Bifidobacterium infantis* ([@bib16]). Forkhead box protein P3 (Foxp3)-expressing intestinal and splenic T-regulatory cells were increased in *B. infantis*--fed mice ([@bib17]) and humans ([@bib18]). This evidence suggests that lactoferrin and *B. infantis* may act synergistically to influence regulatory immune function in addition to having independent effects on the innate and adaptive immune responses, resulting in an improved immune response to a pathogenic challenge.

This study was designed to analyze the immune response to a systemic *S. aureus* infection in piglets fed bLf alone, *B. infantis* alone, or bLf and *B. infantis* in combination. Because bLf and *B. infantis* promote key innate and adaptive immune responses, we hypothesized that bLf in combination with *B. infantis* would be more efficacious at improving the antibacterial immune response and bacterial clearance during a blood-borne infection than either bLf or *B. infantis* alone.

Methods {#sec2}
=======

Animal protocol and diets {#sec2-1}
-------------------------

All of the animal care and experimental procedures were approved by the Institutional Animal Care and Use Committee at the University of Illinois. Pregnant sows (*n* = 15) at the University of Illinois Swine Research Center were monitored for farrowing beginning on day 110 of gestation, and female piglets (*n* = 49) were removed before ingestion of colostrum. Due to the close proximity of the umbilicus and urethral opening in male piglets, females were selected to avoid soaking of bandages and urethral catheters with urine. Piglets were randomly assigned to treatment group on the basis of birth weight and litter. All pigs weighed ∼1.5 kg at birth. To provide passive immunity, sow serum was administered to the piglets via oral gavage at a volume of 5 mL/kg body weight (BW) at birth and at 12, 24, and 36 h postpartum. Piglets were individually housed in cages in environmentally controlled rooms (25°C). Plastic heating pads in each enclosure were used to maintain an ambient temperature of 30°C. Piglets were fed a nonmedicated, sow-milk replacer formula (Liqui-Wean Advance; Milk Specialties Global Animal Nutrition) with either 4 g supplemental protein/L as whey protein \[control (CON) group; Provon 192; Glanbia\] or as bLf (LF group; Bioferrin 2000; Glanbia). This dose of bLf was chosen on the basis of our previous research ([@bib15], [@bib19]), and whey was added to the CON diet to keep the diets isonitrogenous. Piglets were fed 20 times daily, totaling 360 mL ⋅ kg BW^−1^ ⋅ d^−1^. Half of the piglets in each group were further randomly assigned to receive *B. infantis* (3 × 10^9^ CFUs/d)---whey + *B. infantis* (BI group) and bLf + *B. infantis* (COMB group)---resulting in 4 treatment groups: LF, CON, BI, and COMB.

*B. infantis* preparation, storage, and administration {#sec2-2}
------------------------------------------------------

*B. infantis* ATCC 15697 (American Type Culture Collection) was grown from a frozen stock in deMan, Rogosa, Sharpe broth (Difco) supplemented with cysteine (0.05%) and incubated anaerobically as previously described ([@bib20]). Midexponential phase *B. infantis* was harvested by centrifugation, resuspended in sterile PBS, and cryogenically preserved in a 1:1 cell to glycerol (25%) suspension. Each batch of *B. infantis* inoculum was validated for viability on Reinforced Clostridial Agar. On average, each stock contained 5 × 10^8^ CFUs/mL. Before administration, *B. infantis* was washed in PBS, and the bacterial pellet was resuspended in PBS for administration. Piglets in the BI and COMB groups were orally gavaged with 2 mL washed *B. infantis* 3 times daily for a total dosage of ∼3 × 10^9^ CFUs/d. This dose was selected on the basis of typical probiotic dosing regimens ([@bib21]--[@bib23]).

Umbilical catheterization {#sec2-3}
-------------------------

Piglets underwent a surgical procedure within 12 h of birth to place 2 umbilical catheters with the use of established methods ([@bib24]). One catheter was used for administering the *S. aureus* and the other for blood sampling. Briefly, piglets were lightly sedated with 2% isoflurane (IsoFlo; Abbott Laboratories). The abdomen was washed and an iodine disinfectant applied to the umbilicus and surrounding region. To numb the umbilicus, lidocaine (Henry Schein) was injected subcutaneously into multiple sites surrounding the umbilical stump. One catheter (3.5-F polyvinyl chloride catheter; Tyco Healthcare Group) was inserted 22 cm into the dorsal aorta to a position near the heart. A second catheter for blood sampling was inserted and advanced 20 cm. Catheters were sutured to the umbilical stump and secured to the body with suture and elastic tape. Piglets were fitted into a jacket to protect the catheterization site while allowing free movement within the cages. Catheter patency was maintained by flushing twice daily with heparinized saline (10 IU heparin/mL in 0.9% NaCl). Piglets received 1 systemic dose of Enrofloxacin (2.5 mg/kg; Bayer) immediately after surgery.

*S. aureus* infection {#sec2-4}
---------------------

*S. aureus* strain S54F9 was a gift from Dr. Bent Aalbaek, (University of Copenhagen, Denmark) ([@bib25]). *S. aureus* was cultured in Brain Heart Infusion broth aerobically at 37°C. Before administration, stationary-phase *S. aureus* cells were harvested by centrifugation, resuspended in 0.9% sterile isotonic saline, and diluted to 10^5^ CFUs/mL. On day 7, all piglets were administered *S. aureus* at 1 mL/kg BW via the umbilical catheter. This dose was chosen on the basis of a pilot study in which the temporal clinical signs and immune responses to 2 *S. aureus* doses (10^3^ and 10^5^ CFUs) were evaluated and compared with noninfected piglets ([@bib26]).

Sample collection {#sec2-5}
-----------------

BW and formula intake were assessed daily. Rectal temperature and activity were assessed every 12 h postinfection. Blood samples were collected into nonheparinized vacuum tubes via the sampling umbilical catheter before infection and every 12 h postinfection for cytokine analyses. Heparinized blood was collected at 72 and 120 h postinfection for peripheral blood mononuclear cell (PBMC) isolation. Before infection and at 120 h postinfection, fresh blood smears were collected for complete blood counts (Clinical Pathology Laboratory, Hematology Department, University of Illinois College of Veterinary Medicine, Urbana, Illinois). At 120 h postinfection, piglets were killed by using an intravenous injection of sodium pentobarbital (72 mg/kg BW; Fatal Plus; Vortech Pharmaceuticals).

Measuring *B. infantis* in ascending colon contents and feces {#sec2-6}
-------------------------------------------------------------

### DNA extraction {#sec2-6-1}

Total genomic DNA was isolated from ascending colon (AC) contents and feces by using a combination of bead beating and the QIAamp Fast DNA Stool Mini Kit (Qiagen). Approximately 200 mg AC or feces were combined with 1 mL InhibitEx buffer in a 2-mL Lysing Matrix B tube. Tubes were shaken at 6 m/s for 30 s with the use of the Fastprep 24 System (MP Biomedicals). Samples were incubated at 95°C for 5 min and centrifuged at 20,800 × *g* for 1 min at RT. DNA was purified from 200 μL supernatant by using the QIAmp Fast DNA Stool Mini Kit according to the manufacturer\'s instructions. Isolated DNA was quantified with a NanoDrop 1000 spectrophotometer (ThermoFisher Scientific).

### RT-qPCR {#sec2-6-2}

The absolute abundance of *B. infantis* in AC contents and feces was quantified by qPCR with the use of the primers BiINF-1 and BiINF-2 ([@bib27]). PCR was performed with an Applied Biosystems 7900HT Fast Real-Time PCR System with the use of SYBR Green assays. PCR was run in triplicate with a reaction volume of 10 µL:5 µL of 2× Power SYBR Green PCR Master mix (Applied Biosystems), 1 µL BSA (1mg/mL; New England Biolabs), 0.5 µM of each primer, and 10 ng template DNA. The cycling conditions were 50°C for 2 min, 95˚C for 10 min, followed by 40 cycles of 95˚C for 15 s, 5°C for 20 s, and 72°C for 60 s. After amplification, a dissociation step was included to analyze the melting profile of the amplified products. Standard curve \[10^2^--10^7^ 16S ribosomal RNA (rRNA) gene copies/reaction\] was generated by using purified pCR 4 TOPO-TA plasmids (ThermoFisher Scientific) containing the 16S rRNA genes of *B. infantis*. Data were processed with SDS version 2.3 software (ThermoFisher Scientific).

Flow cytometry to identify PBMC subpopulations {#sec2-7}
----------------------------------------------

PBMCs were obtained by Ficoll-Hypaque centrifugation of heparinized blood. Cells were resuspended in flow staining buffer (PBS, 1% BSA, 0.1% sodium azide). Cell populations were assessed by flow cytometry with the use of fluorescently labeled antibodies as described ([@bib28]). Cell staining antibody cocktails are presented in [**Supplemental Table 1**](#sup1){ref-type="supplementary-material"}.

T lymphocyte populations were expressed as a percentage of CD3^+^ events for CD3^+^CD4^+^CD8^−^ (T-helper cells), CD3^+^CD4^−^CD8^+^ (cytotoxic T cells), and CD3^+^CD4^+^CD8^+^ (memory T cells). NK cells were identified as CD3^−^CD4^−^CD8^+^ events and expressed as a percentage of CD3^−^ events. Monocytes were identified as CD14^+^CD163^+^CD172a^+^ events and expressed as a percentage of CD172a^+^ events. B cells were identified as CD21^+^MHCII^+^ events and expressed as a percentage of total lymphocytes.

Serum cytokines {#sec2-8}
---------------

Serum was obtained by centrifugation of blood samples and was analyzed by using porcine-specific ELISA kits for IFN-γ \[limit of detection (LOD): 62.5 pg/mL\], IL-6 (LOD: 125 pg/mL), and IL-10 (LOD: 23.4 pg/mL) (R&D Systems). IL-10 was measured in blood samples taken preinfection and every 12 h postinfection. IFN-γ was measured in blood samples taken preinfection and 24, 36, and 72 h postinfection. IL-6 was measured in blood samples taken preinfection and 72 h postinfection. For samples with concentrations below the LOD of the assay (the lowest point on the standard curve), the value was set to one-half the LOD ([@bib29]).

Detecting *S. aureus* in blood and tissue samples {#sec2-9}
-------------------------------------------------

Immediately after killing, blood was collected by cardiac puncture into heparin-laced vials. Five grams of whole-organ cross-sections for the kidneys (each section included cortex and medulla), lungs (each section included caudal lobe), heart (each section included apex, left and right ventricles), and spleen were collected. Tissues were homogenized at a 1:5 dilution in sterile PBS by using a stomacher (Stomacher 80 Biomaster; Seward Laboratory Systems, Inc.). For each tissue sample, 3 cultures were started on mannitol salt agar (BD), a selective and differential media for *S. aureus:* 200 µL was hand-plated at 1:5, 50 µL was spiral-plated (Neu-Tec Group, Inc.) at 1:5, and 50 µL was spiral-plated at 1:10. Blood samples were plated undiluted on mannitol salt agar. All tissue samples were plated in triplicates at each dilution. Plates were incubated for 48 h aerobically at 37°C before being counted. Colony counts were averaged for each set of triplicates and corrected for the dilution factor. Final results for *S. aureus* load are expressed as CFUs per gram of tissue.

Tissue cytokine analysis {#sec2-10}
------------------------

### RNA extraction {#sec2-10-1}

Frozen kidney, lung, and spleen samples (100 mg) were homogenized with 1 mL TRIzol reagent per the manufacturer\'s instructions (ThermoFisher Scientific). RNA was dissolved in 20 µL nuclease-free water (ThermoFisher Scientific) and quantified by using a NanoDrop 1000 instrument (ThermoFisher Scientific). Samples were diluted to an RNA concentration of ≤500 ng/µL, and RNA quality was determined by using a 2100 Bioanalyzer (Agilent Technologies, Inc.).

### RT-qPCR {#sec2-10-2}

Samples with an RNA integrity number \>6 were transformed into cDNA by using a high-capacity cDNA reverse-transcription kit (ThermoFisher Scientific). PCR was performed by using TaqMan gene expression assays for interferon γ (*IFNG*; Ss03391053_g1), *IL10* (Ss03382372_u1), and Toll-like receptor 2 (*TLR2*; Ss03381278_u1). The expression of the 60S ribosomal protein L19 (*RPL19*; Ss03375624_g1) gene was used as an endogenous control. The relative standard curve method was used for quantitation. Standard curves consisted of dilutions of cDNA created from spleen mRNA pooled from piglets in all of the treatment groups. Normalized values for each target were calculated by dividing the target quantity mean by the ribosomal protein L19 (RPL-19) quantity mean. A fold-difference was calculated for each measurement by dividing the normalized target values by the normalized calibrator sample. Piglets fed whey (CON) were used as the calibrator in each instance.

Statistical analysis {#sec2-11}
--------------------

Statistical analyses were performed by using SAS version 9.2 (SAS Institute). BW, rectal temperatures, serum cytokines, and immune cells were compared between groups by repeated-measures ANOVA with the use of PROC MIXED with treatment (bLf or no bLf), probiotic (received or did not receive *B. infantis*), and time as fixed effects. The model also included all interactions of treatment by time, treatment by probiotic, and probiotic by time. Because some preinfection measurements were missing, complete blood count or differential data were analyzed by 1-factor ANOVA (treatment) by using PROC GLM. RT-qPCR data were analyzed by 1-factor ANOVA (treatment) with the use of PROC GLM. The statistical model for these data included fixed effects for treatment (bLf or no bLf), probiotic (received or did not receive *B. infantis*), and the interaction between treatment and probiotic. Staphylococcal load was analyzed by using a nonparametric Wilcoxon's rank-sum test on CFUs per gram, where the one-sided *Z*-statistic was used due to a sample size \>10. In the event of a significant main effect, a post hoc least significant difference test was used. The abundances of *B. infantis* are presented as means (log~10~ copies per gram of content) ± SDs. The number of 16S rRNA gene copies was log~10~-transformed before analysis. To compare *B. infantis* abundance, statistical analysis was performed by using the PROC MIXED procedure of SAS version 9.2 (SAS Institute) with Tukey's post hoc tests. Fixed effects included diet, probiotic, and the interaction of diet and probiotic. Replicate was included as a random effect. When the abundance of *B. infantis* was below the LOD (2 × 10^5^ copies of 16S rRNA genes/g content), one-half the value of the LOD was used. The occurrence of *B. infantis* among treatments was analyzed by Fisher\'s exact test. Significance was defined as *P* \< 0.05, and trends are reported as *P* \< 0.10. Unless otherwise stated, data are presented as means ± SEMs.

Results {#sec3}
=======

Formula intake, BW, and survival {#sec3-1}
--------------------------------

All of the piglets were fed an additional 4 g protein/L. CON and BI pigs were fed whey protein. LF and COMB pigs were fed bLf. Formula intake was unaffected by treatment or infection and averaged 793 ± 30 mL/d on days 1--7 and 1092 ± 27 mL/d after infection between days 7 and 12 postpartum. Thus, mean supplemental protein intake was 4 g/d at day 7 and 4.8 g/d at day 12. Before infection, all of the piglets had similar BWs. The addition of the probiotic *B. infantis* to either of the diets had no effect on BW; therefore, values were pooled by bLf supplement: bLf-supplemented (LF and COMB) and non--bLf-supplemented (CON and BI) ([**Figure 1**](#fig1){ref-type="fig"}). After infection, bLf-supplemented piglets weighed more than non--bLf-supplemented piglets (treatment × time, *P* \< 0.0001). At the end of the study, bLf-supplemented piglets weighed 3.7 ± 0.1 kg and non--bLf-supplemented piglets weighed 3.4 ± 0.1 kg ([Figure 1](#fig1){ref-type="fig"}). Four piglets died during the experiment (1 LF, 2 BI, and 1 COMB) and were not included in the analyses. The LF piglet showed failure to thrive throughout the experiment. The other 3 piglets died 1, 2, or 3 d postinfection. Although these postinfection deaths could be attributed to the *S. aureus* infection, the piglets' growth and rectal temperatures postinfection did not differ from those of piglets that survived the study.

![Body weight of piglets fed formula from birth and infected with *Staphyloccus aureus* on day 7 postpartum. Before infection all piglets had similar body weights. The addition of the probiotic *Bifido infantis* had no effect on body weight; therefore, groups were pooled by bLf supplement: bLf-supplemented (bLf; LF and COMB) and non--bLf-supplemented (no bLf; CON and BI) piglets. After infection, on days 10, 11, and 12, bLf-supplemented piglets weighed more than non--bLf-supplemented piglets (treatment × time, *P* \< 0.0001). Values are means** **± SEMs. \**P* \< 0.05 between no bLf and bLf. bLf, bovine lactoferrin; BI, group receiving *B. infantis;* COMB, piglets fed bovine lactoferrin and receiving *B. infantis*; CON, control formula group; LF, bovine lactoferrin formula group.](nzy001fig1){#fig1}

Rectal temperature {#sec3-2}
------------------

Rectal temperatures peaked 36 h postinfection and remained elevated until killing at 120 h postinfection. *B. infantis* had no effect on rectal temperatures; therefore, temperatures were pooled by bLf supplement: bLf-supplemented (LF and COMB) and non--bLf-supplemented (CON and BI). Postinfection, there was a significant overall effect in which bLf-supplemented piglets had greater rectal temperatures than non--bLf-supplemented piglets (*P* = 0.01), with no interaction between protein supplement and hour. On average, postinfection rectal temperatures in bLf-supplemented piglets were 0.21°C higher than those in non--bLf-supplemented piglets. Rectal temperatures differed by time (*P* \< 0.0001). All of the piglets had elevated rectal temperatures at 36 h postinfection compared with baseline and 12 or 24 h postinfection. All of the piglets continued to have elevated rectal temperatures until being killed at 120 h postinfection. At baseline, just before infection, piglets had rectal temperatures of 39.2° ± 0.2°, 39.1° ± 0.2°, 39.0° ± 0.1°, and 39.1° ± 0.1°C for CON, BI, LF, and COMB diets, respectively. At 36 h postinfection, piglets had rectal temperatures of 39.3° ± 0.1°, 39.5° ± 0.2°, 40.0° ± 0.2°, and 39.7° ± 0.2°C for CON, BI, LF, and COMB diets, respectively.

Detection of *B. infantis* in AC and feces {#sec3-3}
------------------------------------------

*B. infantis* was detected more frequently in the AC and feces from piglets inoculated with *B. infantis* than in noninoculated pigs (94.4% compared with 4.2% in AC; 100% compared with 5% in feces; *P* \< 0.0001) ([**Supplemental Table 2**](#sup1){ref-type="supplementary-material"}). The occurrences of *B. infantis* were similar in BI and COMB (the treatment groups that included probiotic) pigs. The occurrences *B. infantis* were significantly higher in BI and COMB piglets than in CON and LF piglets (the treatment groups without probiotic) in both sampling sites. bLf had no effect on the abundance of *B. infantis. B. infantis* abundance was greater in both AC and feces of BI (7.0 ± 1.1 and 7.2 ± 1.0 log~10~ copies/g, respectively) and COMB (7.5 ± 1.4 and 7.4 ± 1.0 log~10~ copies/g, respectively) piglets than in CON and LF (*B. infantis* was detected in only 1 LF AC sample and 1 CON fecal sample) piglets. In both AC and fecal samples, the abundance of *B. infantis* did not differ between BI and COMB groups.

Peripheral blood cell populations {#sec3-4}
---------------------------------

Blood cell populations were assessed pre- and 120 h postinfection by using cell counts from whole-blood smears. *B. infantis* administration had no effect on whole-blood cell populations. However, bLf influenced circulating cell populations ([**Supplemental Table 3**](#sup1){ref-type="supplementary-material"}). Before infection, the peripheral blood from bLf-supplemented piglets (LF and COMB) had more lymphocytes and tended to have fewer neutrophils than the blood from non--bLf-supplemented piglets (CON and BI). Postinfection, only 1 pig (in the BI group) met the immature-to-total neutrophil ratio cutoff (\>0.25) indicative of sepsis ([@bib30]). On average, bLf-supplemented piglets had 43% ± 3.7% and non--bLf-supplemented piglets had 31% ± 3.0% blood lymphocytes. bLf-supplemented piglets had 53% ± 3.8% and non--bLf-supplemented piglets had 62% ± 3.4% blood neutrophils. After infection, nucleated RBC (NRBC) populations were lower (*P* = 0.047) in bLf-supplemented piglets than in non--bLf-supplemented piglets. On average, NRBCs were 3.5% ± 0.9% and 7.3% ± 1.7% of total blood cells in bLf-supplemented and non--bLf-supplemented piglets, respectively. With the use of PBMCs isolated by density gradient centrifugation, B cell, T cell, NK cell, and monocyte and macrophage cell populations were assessed at 72 and 120 h postinfection.

B cell populations were similar for all piglets within each time point ([**Table 1**](#tbl1){ref-type="table"}). The percentage increase in PBMC B cells from 72 to 120 h postinfection differed by protein supplement group, with bLf-supplemented piglets experiencing a smaller increase in B cell population size than CON piglets (*P* = 0.04).

###### 

Immune cells in isolated PBMCs at 72 and 120 h after *Staphylococcus* (strain S54F9) *aureus* infection in piglets fed control formula, control formula with *Bifidobacterium infantis* administration, or formula with 4 g bLf/L alone or with *B. infantis* administration[^1^](#tb1fn1){ref-type="table-fn"}

         B cells (CD21^+^MHCII^+^), % of total PBMCs   Monocytes (CD14^+^CD163^+^CD172a^+^), % of CD172^+^ cells   Memory T cells (CD4^+^CD8^+^CD3^+^), % of CD3^+^ cells                                                                      
  ------ --------------------------------------------- ----------------------------------------------------------- -------------------------------------------------------- ------------ ------------ ------------- ------------ ------------- ----------
  CON    4.2 ± 0.8                                     10.0 ± 2.9                                                  240 ± 59                                                 18.5 ± 5.2   24.9 ± 7.5   192 ± 74      9.6 ± 1.2    10.7 ± 1.2    119 ± 15
  BI     6.1 ± 1.3                                     11.2 ± 2.6                                                  177 ± 20                                                 20.3 ± 4.2   23.3 ± 5.2   201 ± 71      9.5 ± 0.9    8.3 ± 0.6\*   92 ± 9\*
  LF     6.0 ± 1.1                                     8.4 ± 1.8                                                   151 ± 25\*                                               23.5 ± 4.3   18.6 ± 4.6   102 ± 25^†^   9.2 ± 1.1    10.8 ± 1.2    124 ± 17
  COMB   5.3 ± 1.0                                     6.6 ± 2.0                                                   112 ± 18\*                                               22.3 ± 4.6   18.7 ± 5.1   104 ± 31^†^   10.2 ± 1.4   9.0 ± 0.8\*   91 ± 9\*

Values are means ± SEMs. \*Different by treatment, *P* \< 0.05; ^†^trend to differ by treatment, *P* = 0.07. BI, group receiving *B. infantis* (3 × 10^9^ CFUs/d); bLf, bovine lactoferrin; COMB, piglets receiving *B. infantis* and fed bovine lactoferrin; CON, control formula group; LF, bovine lactoferrin formula group; PMBC, peripheral blood mononuclear cell.

Immune cell percentage at 120 h divided by the immune cell percentage at 72 h × 100.

Monocyte populations were similar for piglets in all 4 treatment groups at both 72 and 120 h postinfection ([Table 1](#tbl1){ref-type="table"}). The percentage difference in PBMC monocytes from 72 to 120 h postinfection in bLf-supplemented piglets tended (*P* = 0.07) to be smaller than that in non--bLf-supplemented piglets ([Table 1](#tbl1){ref-type="table"}).

Neither T-helper (70.2% ± 8.4%) nor cytotoxic T cell (5.3% ± 0.6%) populations differed between treatment groups at either time point. However, in an analysis measuring only the effect of treatment at 120 h postinfection, memory T cell populations were smaller (*P* = 0.03) in piglets that received *B. infantis* than in piglets that did not receive the probiotic ([Table 1](#tbl1){ref-type="table"}). The percentage difference in PBMC memory T cell populations from 72 to 120 h postinfection in probiotic supplemented piglets was lower (*P* = 0.03) than the percentage difference in memory T cell populations from 72 to 120 h postinfection in non--probiotic-supplemented piglets.

NK cell populations were similar for all piglets at each time point, but NK cell populations were larger at 120 h postinfection (5.8% ± 1.0%) than at 72 h postinfection (2.6% ± 0.4%).

Serum cytokines {#sec3-5}
---------------

Of the 3 serum cytokines analyzed, only IL-10 was detected in the serum of piglets at multiple time points. Neither IFN-γ nor IL-6 was detectable in piglets before infection nor were these 2 cytokines detectable in the majority of piglets at 72 h postinfection. Before infection on postpartum day 7, there was no effect of probiotic; therefore, data were pooled by bLf-supplemented (LF and COMB) compared with non--bLf-supplemented (CON and BI) piglets. Piglets fed formula with bLf had 3-fold lower (*P* = 0.01) serum IL-10 than non--bLf-supplemented piglets ([**Figure 2A**](#fig2){ref-type="fig"}). After infection, serum IL-10 concentrations changed significantly over time (*P* = 0.03). The highest concentrations of IL-10 were observed at 96 h (58.2 ± 24.0 pg/mL) and 108 h (45.4 ± 16.7 pg/mL) postinfection ([Figure 2B](#fig2){ref-type="fig"}). There was no effect of bLf on serum IL-10 postinfection. Therefore, data were pooled by probiotic treatment. Probiotic*-*treated piglets (BI and COMB) had higher serum IL-10 (*P* = 0.03) concentrations than piglets that did not receive *B. infantis* ([Figure 2B](#fig2){ref-type="fig"}).

![Serum IL-10 concentrations measured before *Staphylococcus aureus* infection and every 12 h postinfection. Preinfection, bLf, but not *Bifidobacterium infantis*, significantly affected serum IL-10; therefore, groups were pooled by bLf (LF and COMB; *n* = 26) or non-bLf (CON and BI; *n* = 23). Before infection, bLf-supplemented piglets had lower (*P* = 0.01) serum IL-10 concentrations than non--bLf-supplemented piglets (A). After *S. aureus* infection, there was a main effect of time (*P* = 0.03), in which piglets produced the highest IL-10 concentrations at 96 and 108 h postinfection (B). There was also a main effect of probiotic (*P* = 0.03), but not bLf; therefore, values were pooled for probiotic (BI and COMB; *n* = 26) and no probiotic (CON and LF; *n* = 23). Probiotic-treated piglets had greater serum IL-10 than non--probiotic-treated piglets. Values are means** **± SEMs, *n* = 11--13/group. \**P* \< 0.05. Different letters on each time point, *P* \< 0.05. BI, group receiving *B. infantis*; bLf, bovine lactoferrin; COMB, piglets fed bovine lactoferrin and receiving B. infantis; CON, control formula group; LF, bovine lactoferrin group.](nzy001fig2){#fig2}

*S. aureus* in blood and tissues {#sec3-6}
--------------------------------

*S. aureus* was detected in the kidneys, lungs, heart, and spleen, but not in the blood. There was no effect of *B. infantis* on *S. aureus* content in blood or tissues; therefore, data were pooled by bLf supplement ([**Figure 3**](#fig3){ref-type="fig"}). bLf-supplemented pigs had lower numbers (CFUs) of *S. aureus* in the kidneys (*P* = 0.02) and tended to have lower numbers in the lungs (*P* = 0.07) and heart (*P* = 0.06) than piglets fed diets without bLf. There was no effect of bLf on *S. aureus* numbers in the spleen. Overall, dietary bLf decreased kidney, lung, and heart *S. aureus* load by 7.3-, 4-, and 1.8-fold, respectively.

![*Staphylococcus aureus* counts (CFUs per gram) in the heart, kidneys, lungs, and spleen 120 h after *S. aureus* infection in 12-d-old piglets fed control formula, control formula with *Bifidobacterium infantis* administration (10^9^ CFU/d), or formula with 4 g bLf/L alone or with *B. infantis* administration. There was no effect of *B. infantis*; therefore, values were pooled by bLf supplement: bLf-supplemented (LF and COMB, bLf; *n* = 26) and non--bLf-supplemented (CON and BI, no bLf; *n* = 23). No differences were detected in the spleen. Piglets fed diets containing bLf had decreased *S. aureus* counts in the kidneys and tended to have decreased CFUs per gram in the lungs and heart. Values are means** **± SEMs. \**P* \< 0.05 and ^†^0.05 \> *P* \< 0.1 between no bLf and bLf. BI, group receiving *B. infantis*; bLf, bovine lactoferrin; COMB, piglets fed bovine lactoferrin and receiving B. infantis; CON, control formula group; LF, bovine lactoferrin formula group.](nzy001fig3){#fig3}

Immune gene expression in the tissues {#sec3-7}
=====================================

Kidney {#sec3-7-1}
------

Piglets exposed to *B. infantis* in the context of a whey protein diet (BI) had the highest (*P* = 0.01) kidney TLR2 mRNA expression. However, piglets exposed to *B. infantis* in the context of a bLf diet (COMB) had renal TLR2 mRNA expression similar to that of CON or LF piglets ([**Table 2**](#tbl2){ref-type="table"}). Pigs fed diets with bLf (LF and COMB) showed decreased renal IL-10 expression (*P* = 0.03). Piglets administered *B. infantis* in the absence of dietary bLf (BI) tended (*P* = 0.09) to have the highest renal IL-10 expression. Renal IFN-γ expression was similar in all piglets.

###### 

Immune-related gene expression in kidneys, lungs, and spleen at 120 h after *Staphylococcus aureus* (strain S54F9) infection in piglets fed control formula, control formula with *Bifidobacterium infantis* administration, or formula with 4 g bLf/L alone or with *B. infantis* administration[^1^](#tb1fn2){ref-type="table-fn"}

         Kidneys     Lungs         Spleen                                                                        
  ------ ----------- ------------- ------------- ------------- ----------- ----------- ------------- ----------- -----------
  CON    1.0 ± 1.0   1.0 ± 0.16    1.0 ± 0.3     1.0 ± 0.3     1.0 ± 0.2   1.0 ± 0.2   1.0 ± 0.2     1.0 ± 0.1   1.0 ± 0.1
  BI     1.2 ± 1.1   2.5 ± 0.6\*   2.3 ± 1.0     0.9 ± 0.3     0.9 ± 0.2   1.0 ± 0.3   2.5 ± 2.1\*   1.2 ± 0.1   1.0 ± 0.1
  LF     0.6 ± 0.5   1.1 ± 0.1     0.4 ± 0.1\*   2.0 ± 0.5\*   0.9 ± 0.1   1.6 ± 0.5   1.1 ± 0.3     1.4 ± 0.2   1.1 ± 0.2
  COMB   1.2 ± 1.3   1.3 ± 0.2     0.7 ± 0.2\*   1.5 ± 0.4\*   1.2 ± 0.3   1.4 ± 0.6   2.7 ± 0.8\*   1.2 ± 0.3   1.0 ± 0.2

A fold-difference was calculated for each measurement by dividing the normalized target values (calculated by dividing the target quantity mean by the RPL-19 quantity mean) by the normalized calibrator values. For samples from the same tissue, values for CON piglets were used as the calibrator. \*Different by treatment, *P* \< 0.05. BI, group receiving *B. infantis* (3 × 10^9^ CFUs/d); bLf, bovine lactoferrin; COMB, piglets receiving *B. infantis* and fed bovine lactoferrin; CON, control formula group; LF, bovine lactoferrin formula group; RPL-19, ribosomal protein L19; TLR2, Toll-like receptor 2.

Lungs {#sec3-7-2}
-----

IFN-γ expression was significantly higher in LF and COMB piglets than in CON and BI piglets ([Table 2](#tbl2){ref-type="table"}). No significant differences in TLR2 or IL-10 mRNA expression in the lungs were observed.

Spleen {#sec3-7-3}
------

Piglets exposed to *B. infantis* showed higher (*P* = 0.02) splenic IFN-γ mRNA expression ([Table 2](#tbl2){ref-type="table"}) than piglets that were not given the probiotic. Splenic TLR2 and IL-10 mRNA expression was similar in all piglets.

Discussion {#sec4}
==========

The goal of this study was to investigate the individual and combined effects of bLf and *B. infantis* on the clinical course of a systemic *S. aureus* infection in neonatal piglets. This research was predicated on previous clinical trials that showed that orally administered bLf reduced the incidence of late-onset sepsis in very-low-birth-weight infants colonized with gram-positive bacteria, including *Staphylococcus* species ([@bib3]). Furthermore, *B. infantis* has been shown to be immunomodulatory ([@bib17], [@bib31]) and bLf may promote the growth of *B. infantis* ([@bib16]), suggesting the potential for synergistic effects. On the basis of our previous research ([@bib15], [@bib19]), by the seventh day of life bLf improved gastrointestinal development and immune system development compared with piglets fed formula alone. Thus, these early effects on the gastrointestinal and immune systems likely give the bLf-fed piglets an advantage over their formula-fed peers upon systemic challenge with *S. aureus*.

Despite promising clinical outcomes, the immune response is difficult to assess in human infants; thus, the systemic and tissue immune responses over the course of *S. aureus* infection were assessed by using newborn piglets. The piglet is an excellent preclinical model for this research for the following reasons: *S. aureus* is a dominant cause of widespread septicemia in pigs and humans ([@bib32]); swine physiology, immune response; and anatomy are highly similar to those of humans ([@bib33]); and most importantly, pigs are capable of reproducing the gradual pathophysiologic changes and clinical characteristics of neonatal sepsis ([@bib34]), including BW and temperature, which are easily monitored in piglets. The use of bLf in this appropriate preclinical model for human infants was deliberate because this is the same compound that can be used in human infant formulas. In the current study, dietary bLf and *B. infantis* each influenced the response to *S. aureus* infection in the neonatal piglet, but the combination of bLf and *B. infantis* did not exert synergistic effects. Overall, the severity of *S. aureus* infection was reduced in piglets fed dietary bLf, with limited beneficial effects of *B. infantis*.

Dietary bLf improved weight gain after *S. aureus* infection. The beneficial effect of bLf on growth cannot be attributed to the presence of additional protein, because the CON and BI diets were supplemented with 4 g whey protein/L to maintain a protein content similar to the LF and COMB diets (supplemented with 4g bLf/L). Previous studies have shown that bLf improves weight gain in piglets ([@bib35]) and human infants ([@bib36]). The increase in BW has been partially attributed to its proposed role in regulating the immune system and providing protection against microbial infection, wherein animals that more effectively respond to infection have a reduced period of cachexia and can apportion more energy toward growth instead of directing that energy toward a sustained immune response.

A key finding of this study was that dietary bLf significantly reduced bacterial abundance in the kidneys and tended to lower the *S. aureus* counts in the lungs and hearts of infected piglets. The improved bacterial clearance in the presence of bLf was likely due, in part, to an enhanced Th1 immune response in bLf-supplemented pigs. In our study, bLf supplementation increased IFN-γ mRNA expression in the lungs after infection, indicating a Th1 response. Furthermore, bLf-supplemented pigs had less serum IL-10 on day 7 postpartum just before *S. aureus* infection. A high concentration of IL-10 is known to inhibit Th1 immune responses ([@bib37]). Others have shown that lactoferrin-transgenic mice showed an enhanced Th1 response to *S. aureus* infection. These mice showed a greater IFN-γ response and increased ability to clear the bacterial infection ([@bib13]).

Accordingly, *S. aureus* persistence was affected by dietary treatment*.* As in previous studies ([@bib25], [@bib38]), *S. aureus* was rapidly cleared from the blood of infected piglets but persisted in other tissues. Compared with supplementation with whey protein (CON, BI), supplementation with bLf (COMB, LF) significantly reduced *S. aureus* load. This was expected on the basis of previous reports in rodents in which bLf supplementation reduced *S. aureus* load in the kidneys of *S. aureus--*challenged mice ([@bib14]) and where Lf-transgenic mice showed an increased ability to clear *S. aureus* after a challenge ([@bib13]). Importantly, bLf supplementation decreased *S. aureus* counts in the kidneys and tended to decrease counts in the lungs and heart.

In contrast, the probiotic *B. infantis* had no effect on bacterial clearance when administered alone. This may be related to increased TLR2 message and IL-10 message as well as IL-10 protein in these piglets. In vitro work has shown that *S. aureus* downregulates the inflammatory T cell response by triggering IL-10 production by monocytes via TLR2 activation ([@bib39], [@bib40]). The increased IL-10 dampens the immune response, enabling *S. aureus* to colonize the host ([@bib40]). Consistent with the IL-10 serum cytokine data, probiotic-treated piglets also had fewer circulating memory T cells, with significantly fewer memory T cells compared with non--probiotic-treated piglets at 120 h postinfection. In the kidneys, the enhanced TLR2 and IL-10 mRNA expression in response to probiotic treatment was decreased when bLf was present. In fact, the presence of bLf also decreased the renal IL-10 message compared with the CON diet. However, because the effects were not consistent across tissues (kidneys, lungs, spleen, blood), other mechanisms may be at work. TLR2 signaling regulates additional inflammatory cytokine responses ([@bib41], [@bib42]), and *S. aureus* stimulates additional immune receptors so effects of bLf and *B. infantis* on other cytokines are also important. For instance, bLf supplementation increased IFN-γ expression in the lungs. It is important to note that bLf may not only have decreased bacterial load but also may have impaired *S. aureus* viability, leading to these lower tissue counts.

We hypothesized that bLf would stimulate a robust Th1 immune response. Because *B. infantis* is known to downregulate inflammatory responses ([@bib17]), we hypothesized that *B. infantis* would provide protection in the later phase of infection. In addition, bLf has been shown to promote growth of *B. infantis* in vitro ([@bib16]), suggesting a potential mechanism by which these dietary components could synergize. In this experiment, bLf did not support the growth of *B. infantis* over that seen in piglets exposed to *B. infantis* in the absence of bLf. However, we observed that bLf supplementation was most important for *S. aureus* bacterial clearance. Postinfection, *B. infantis* had an overall effect of increased serum IL-10, which is consistent with what has been observed in mice and humans supplemented with *B. infantis* ([@bib17], [@bib18]). High concentrations of IL-10 have consistently been shown to be a strong indicator of septic shock and a predictor of mortality during infection due to its broadly immunosuppressive function ([@bib43]). Consistent with this, the only piglet to have reached the diagnostic immature-to-mature neutrophil ratio for sepsis ([@bib44]) was in the BI group. Furthermore, probiotic-treated pigs had higher postinfection NRBC counts. NRBCs are another cell population that has been associated with septicemia ([@bib45]). It has been shown that, in addition to promoting a Th1 response through increased IFN-γ production, bLf can also increase the IL-12-to-IL-10 ratio in LPS-stimulated splenocytes to promote the Th1 response ([@bib46]). The presence of IL-12, a cytokine that promotes the Th1 response, in addition to IFN-γ, leads to a significantly decreased production of IL-10 ([@bib46]). However, in our studies, we did not measure IL-12 and no IFN-γ was detected in the serum. One possible explanation for this could be that IFN-γ is an intracellular cytokine and its presence may be too low in the serum to detect. Previously, we found that spleen cells isolated from pigs fed bLf produced more IFN-γ and TNF-α than cells isolated from pigs fed a control diet ([@bib15]). Although NK cells are the most likely potential sources of IFN-γ, it may be that peripheral memory T cells contain intracellular IFN-γ; both of these cells could release IFN-γ when needed during an immune response. Future experiments should use intracellular cytokine staining in combination with flow cytometry or ELISpot assays to determine the IFN-γ production potential of cells isolated from areas local to the infection.

Despite the novelty of the model, the study described herein has several limitations. Neither iron status nor amounts of bLf in stool and serum were measured. Therefore, the current study could not assess the fate of ingested bLf nor determine if the effects of bLf on *S. aureus* infection were due to bLf sequestration of iron from *S. aureus*. This study was designed to test the regulatory and adaptive immune response to *S. aureus* infection, based on the hypothesis that those would be the stages of the immune response during which the effects of combining probiotic and bLf treatment would be most efficacious at reducing the severity of *S. aureus* infection. Therefore, most details about the effects of the dietary treatments on the early immune response to *S. aureus* infection are unknown. However, blood was collected preinfection and every 12 h postinfection for some analyses. IFN-γ was measured preinfection and at 24, 36, and 72 h postinfection. IL-6 was measured preinfection and at 72 h postinfection. These time points were chosen on the basis of a pilot study. Because a limited volume of blood could be sampled (due to piglet size and the repeated sampling design), blood was used for cytokine analyses rather than *S. aureus* quantification at the early time points postinfection. Thus, conclusions about the effects of the dietary treatment on *S. aureus* counts in the blood at early time points postinfection cannot be drawn. Finally, although the presence of *B. infantis* was determined in feces and AC content; no attempt was made to test for *B. infantis* in the blood or other tissues. Therefore, any effects that the potential translocation of the probiotic from the gut to the bloodstream could have on the immune response to infection are unknown. Future studies should measure bLf in fecal matter, serum, and urine and should carefully assess the iron status (ferritin, transferrin, free iron) of subjects. Additional studies should also examine the effects of probiotic and bLf on early inflammatory and innate immune responses to infection.

This preliminary animal study provides mechanistic insight supporting clinical studies that show the effectiveness of orally administered bLf in the prevention of systemic *S. aureus* infections and suggests that future studies investigating lactoferrin\'s role in treating *S. aureus* are warranted. IL-10 is a critically important predictor of mortality during infection. Therefore, the observation that bLf lowers serum IL-10 preinfection and B. infantis increases serum IL-10 postinfection provides evidence that modulation of IL-10 is one potential mechanism by which bLf reduces tissue bacterial abundance in this model of systemic *S. aureus* infection. Furthermore, another indicator of sepsis, NRBC counts, were lower in pigs fed bLf. Although NRBC counts were not affected by the presence of *B. infantis*, exposure to the probiotic increased serum IL-10 concentrations postinfection, potentially indicating that this probiotic should be avoided in neonates at risk of systemic *S. aureus* infection. However, due to its ability to induce IL-10, *B. infantis* may be a useful therapy in already septic neonates. In conclusion, this study suggests that colostrum and mother\'s milk, 2 liquids with abundant lactoferrin concentrations ([@bib47], [@bib48]), may protect neonates from *S. aureus* infections and from the complications caused by such infections.

Supplementary Material
======================

###### 

Click here for additional data file.
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